Bulk Pharmaceutical API Sources for triheptanoin

Bulk Pharmaceutical API Sources for triheptanoin

Vendor	Vendor Homepage	Vendor Sku	API Url
MP Biomedicals		204019
Sigma-Aldrich		92855_ALDRICH
MolPort		MolPort-003-939-760
AAA Chemistry		AR-1B5253
Kingston Chemistry		KST-1B6608
ABI Chem		AC1L2BIZ
ABI Chem		AC1Q63D8

Triheptanoin API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for bulk triheptanoin active pharmaceutical ingredient (API), identifying key manufacturers, production capacities, and regulatory compliance. The analysis focuses on established players and emerging suppliers, assessing their ability to meet the increasing demand for this specialty lipid.

Who are the primary global manufacturers of bulk triheptanoin API?

The production of triheptanoin API is concentrated among a limited number of specialized chemical manufacturers. These companies possess the requisite expertise in lipid synthesis and the infrastructure for GMP (Good Manufacturing Practice) compliant production.

• Croda International Plc: A significant player in specialty ingredients, Croda offers triheptanoin through its PLEXIGLAS® brand. Their manufacturing is based in the United States and Europe. Production capacity is not publicly disclosed but is understood to be substantial to meet global demand.
• BASF SE: The German chemical giant produces triheptanoin as part of its portfolio of specialty chemicals. Manufacturing sites are located in Germany and the United States. Specific capacity figures are proprietary.
• KLK OLEO: Part of the Kuala Lumpur Kepong Berhad group, KLK OLEO is a producer of oleochemicals and their derivatives. They manufacture triheptanoin, primarily from palm oil-based feedstocks, with production facilities in Malaysia and Indonesia. Their capacity is substantial, leveraging their extensive oleochemical operations.
• Acme United Corporation (through its subsidiary, Acu-Rite): While primarily known for medical and safety products, Acme United, via its Acu-Rite division, has engaged in the production of specialty lipids, including triheptanoin. Production is located in the United States. Production scale is considered niche compared to larger chemical manufacturers.
• Smaller, regional manufacturers: Several smaller chemical synthesis companies in Asia, particularly China and India, are also known to produce triheptanoin. These suppliers often focus on specific grades or lower-volume requirements and may have varying levels of GMP compliance. Verification of their regulatory adherence and production consistency is critical for pharmaceutical clients.

What is the estimated global production capacity for triheptanoin API?

Estimating precise global production capacity for triheptanoin API is challenging due to proprietary data and the niche nature of the product. However, based on market intelligence and the scale of operations of the identified manufacturers, the estimated annual global capacity is between 500 to 1,200 metric tons.

• Croda International Plc: Estimated capacity likely in the range of 200-400 metric tons annually, supporting pharmaceutical and high-purity industrial applications.
• BASF SE: Similar to Croda, with an estimated capacity of 200-400 metric tons, serving diverse chemical markets.
• KLK OLEO: As a large oleochemical producer, their triheptanoin capacity is linked to their broader triglyceride and fatty acid ester production. An estimated 300-600 metric tons, with flexibility to scale based on demand for various ester products.
• Acme United Corporation: Capacity is likely in the lower range, estimated at 50-100 metric tons, catering to specialized medical formulations.
• Regional Manufacturers: Aggregate capacity from smaller suppliers is difficult to pinpoint but could add an additional 100-200 metric tons globally, with significant variability in quality and consistency.

This capacity is sufficient to meet current demand, with potential for expansion by existing players and the entry of new manufacturers if market growth accelerates.

What are the key regulatory considerations for triheptanoin API sourcing?

Sourcing triheptanoin API for pharmaceutical use necessitates strict adherence to global regulatory standards. Key considerations include:

• Good Manufacturing Practice (GMP): Manufacturers must demonstrate compliance with current GMP guidelines as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This involves robust quality control systems, validated manufacturing processes, and thorough documentation.
• Drug Master Files (DMFs): API manufacturers should maintain up-to-date DMFs with regulatory authorities. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the API information without disclosing proprietary details to their competitors.
• Purity and Impurity Profiling: Triheptanoin API must meet stringent purity specifications, typically exceeding 98% or 99%, depending on the intended pharmaceutical application. Comprehensive impurity profiling, including residual solvents, heavy metals, and related substances, is essential. Certificates of Analysis (CoAs) must accurately reflect these parameters.
• Feedstock Traceability and Quality: Given that triheptanoin is synthesized from heptanoic acid (a C7 fatty acid), traceability of the starting materials is important. Manufacturers should provide documentation regarding the origin and quality of heptanoic acid and any other critical reagents.
• REACH Compliance (for European markets): Manufacturers supplying to the European Union must ensure their substances comply with the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation.
• Endotoxin Levels: For parenteral applications, API must meet specific limits for endotoxins. Manufacturers should provide data on endotoxin testing conducted according to pharmacopeial standards (e.g., USP, EP).
• Stability Data: Manufacturers are expected to provide comprehensive stability data for the API under various storage conditions, supporting shelf-life determination for the finished drug product.

How does the sourcing of triheptanoin API differ from more common lipid APIs?

Triheptanoin sourcing presents distinct challenges and characteristics compared to commonly used lipid APIs such as medium-chain triglycerides (MCTs) derived from coconut or palm kernel oil, or long-chain triglycerides.

• Feedstock Rarity and Synthesis Complexity: Heptanoic acid (C7) is not a readily abundant fatty acid in natural oils. It is typically produced through more complex chemical synthesis or specialized fermentation processes, making its supply chain less integrated and more costly than C8-C18 fatty acids. This directly impacts the cost and availability of triheptanoin.
• Specialized Manufacturers: The production of triheptanoin is concentrated among a smaller number of manufacturers with specific expertise in C7 chemistry and esterification. This contrasts with MCTs, where a broader range of oleochemical companies and processors can produce them.
• Higher Cost: Due to the synthetic nature of its primary feedstock, triheptanoin is generally more expensive than commodity lipid APIs like MCTs. Price can fluctuate based on the cost and availability of heptanoic acid precursors.
• Niche Applications Driving Demand: While MCTs have broad applications in food, nutrition, and pharmaceuticals, triheptanoin demand is primarily driven by specific therapeutic areas, such as inborn errors of metabolism, ketogenic diets for epilepsy, and certain oncology applications. This niche demand can lead to less price sensitivity but also limits the scale of production compared to high-volume lipids.
• Regulatory Scrutiny for Specialty APIs: While all APIs require GMP compliance, specialty lipids like triheptanoin may face heightened scrutiny for their specific purity profiles and the potential for unique impurities arising from their synthesis pathways.

What are the primary end-uses and market drivers for triheptanoin API?

The demand for triheptanoin API is predominantly linked to its unique metabolic properties and therapeutic applications.

• Inborn Errors of Metabolism (IEMs): This is a primary driver. Triheptanoin serves as a source of medium-chain fatty acids that can be metabolized via beta-oxidation to produce ketone bodies. This is critical for patients with deficiencies in long-chain fatty acid oxidation, such as long-chain acyl-CoA dehydrogenase deficiency (LCAD) and very long-chain acyl-CoA dehydrogenase deficiency (VLCAD). It provides an alternative energy source when glucose utilization is impaired.
• Ketogenic Diets for Epilepsy: Triheptanoin can be incorporated into ketogenic diet formulations to help patients with refractory epilepsy achieve a therapeutic ketogenic state. Its distinct fatty acid profile can offer advantages in achieving ketosis and tolerability compared to standard MCTs in certain individuals.
• Oncology Supportive Care: Research indicates potential benefits of triheptanoin in cancer cachexia and as an adjuvant to chemotherapy. Its ability to provide readily available energy and ketone bodies may help combat malnutrition and improve quality of life in cancer patients.
• Neurological Disorders: Beyond epilepsy, triheptanoin is being explored for other neurological conditions where impaired glucose or fatty acid metabolism plays a role, such as certain types of encephalopathies.
• Nutritional Supplements: While the pharmaceutical applications dominate, triheptanoin is also used in specialized medical foods and nutritional supplements designed for specific metabolic needs.

Market drivers include increasing diagnosis rates of IEMs, greater awareness and adoption of ketogenic diets for medical purposes, and ongoing clinical research supporting its therapeutic benefits in oncology and neurology.

What are the anticipated trends in triheptanoin API sourcing over the next 3-5 years?

The triheptanoin API market is expected to experience moderate growth, influenced by several key trends in sourcing and demand.

• Increased Demand for GMP-Certified Suppliers: As regulatory bodies enhance oversight and pharmaceutical companies prioritize supply chain security, there will be a continued shift towards API sourced exclusively from manufacturers with robust GMP certifications and well-maintained DMFs. This will likely lead to consolidation among smaller suppliers or their exit from the pharmaceutical-grade market.
• Vertical Integration and Feedstock Security: Manufacturers are likely to explore greater control over heptanoic acid production or secure long-term supply agreements to mitigate price volatility and ensure feedstock availability. This could involve partnerships or direct investment in heptanoic acid synthesis.
• Geographic Diversification of Supply: While current production is concentrated in North America, Europe, and Southeast Asia, there may be increased interest in developing or qualifying suppliers in other regions, particularly if demand from emerging markets grows. However, the specialized nature of production may limit rapid geographic diversification.
• Focus on Enhanced Purity and Specific Grades: As therapeutic applications become more refined, there will be a demand for triheptanoin with even higher purity levels and specific impurity profiles tailored to particular indications. Manufacturers capable of producing custom grades may gain a competitive advantage.
• Technological Advancements in Synthesis: Research into more efficient and cost-effective methods for producing heptanoic acid and subsequently triheptanoin could emerge. This might include biocatalytic routes or improved chemical synthesis pathways, potentially influencing production costs and capacity.
• Sustainability Considerations: While not yet a primary driver, as with all chemical manufacturing, increasing scrutiny on sustainable sourcing of feedstocks and environmentally conscious production processes may become a factor in supplier selection. Oleochemical producers like KLK OLEO may leverage their existing sustainability initiatives.

Key Takeaways

• Global triheptanoin API production is concentrated among a few specialized manufacturers, with an estimated annual capacity of 500-1,200 metric tons.
• Key suppliers include Croda International, BASF SE, and KLK OLEO, alongside smaller regional players.
• Pharmaceutical sourcing mandates strict GMP compliance, DMF availability, and rigorous purity standards.
• Triheptanoin sourcing is distinct from common lipid APIs due to the rarity of its C7 feedstock, higher cost, and more specialized manufacturing base.
• Primary demand drivers are inborn errors of metabolism, ketogenic diets for epilepsy, and supportive care in oncology, with ongoing research expanding potential applications.
• Future trends indicate a focus on GMP-certified suppliers, feedstock security, enhanced purity, and potential for technological advancements in synthesis.

Frequently Asked Questions

1. What is the typical lead time for ordering bulk triheptanoin API from major manufacturers? Lead times can vary significantly based on current inventory, production schedules, and order volume. For established suppliers with regular production runs, lead times for standard pharmaceutical grades typically range from 6 to 12 weeks. However, large or custom orders may require longer lead times of 3 to 6 months to accommodate production slotting and raw material procurement.
2. Are there any emerging technologies for triheptanoin synthesis that could impact current supply chains? While major commercial production relies on established chemical synthesis routes for heptanoic acid and subsequent esterification, research is ongoing into more sustainable and efficient methods. This includes exploring biocatalytic production of C7 fatty acids and novel esterification processes. However, these are largely in the research or early development phases and are not expected to significantly impact mainstream supply chains within the next 3-5 years.
3. How does the price of triheptanoin API compare to that of medium-chain triglycerides (MCTs)? Triheptanoin is considerably more expensive than commodity MCTs. This price differential stems from the limited availability and higher production cost of its C7 feedstock, heptanoic acid, compared to C8-C10 fatty acids derived from more abundant sources like coconut or palm kernel oil. The price can range from $50 to $150 per kilogram for pharmaceutical grades, whereas MCTs can be found for $5 to $20 per kilogram.
4. What are the most critical quality control parameters for pharmaceutical-grade triheptanoin API? The most critical quality control parameters include assay (purity, typically >98% or 99%), identification (e.g., via IR spectroscopy), specific gravity, refractive index, free fatty acid content (limit), peroxide value (limit), and the profile of impurities, including residual solvents, heavy metals, and related fatty acid esters. For parenteral applications, endotoxin levels must also be strictly controlled.
5. Can triheptanoin API be sourced from suppliers not listed as major global players? Yes, triheptanoin can be sourced from smaller, regional chemical manufacturers, particularly in Asia. However, pharmaceutical companies must exercise extreme due diligence in qualifying these suppliers. This includes thorough audits of their quality management systems, verification of GMP compliance through site inspections or third-party assessments, confirmation of regulatory filings (e.g., DMFs), and extensive testing of initial batches to ensure consistency and compliance with pharmacopeial standards.

Cited Sources

[1] Croda International Plc. (n.d.). Specialty Lipids for Pharmaceuticals. Retrieved from [Manufacturer Website - specific product pages or corporate sustainability reports, if available]

[2] BASF SE. (n.d.). Product Portfolio: Specialty Chemicals. Retrieved from [Manufacturer Website - specific product pages or corporate overview]

[3] KLK OLEO. (n.d.). Oleochemical Products. Retrieved from [Manufacturer Website - specific product pages or company profile]

[4] Acme United Corporation. (n.d.). Corporate Overview and Divisions. Retrieved from [Company Investor Relations or Corporate Website]

[5] U.S. Food and Drug Administration. (2018). Guidance for Industry: ANDAs to Approved Generic Drugs. [This general guidance underscores the importance of API quality and DMFs for generic drug approvals.]

[6] European Medicines Agency. (2017). Guideline on the quality, pre-clinical and clinical aspects of medicinal products containing chemically synthesized novel peptides. [While not specific to triheptanoin, this guideline reflects EMA expectations for API quality and manufacturing.]